M/s. Delmaw Enterprises Ltd

M/s. Delmaw Enterprises Ltd is a privately held pharmaceutical importer and wholesaler based in Kampala, Uganda. Established over 20 years ago, the company has built a reputation for distributing a wide range of pharmaceutical products, medical devices, and chemicals. As an ISO 9001:2005 certified entity, Delmaw Enterprises Ltd emphasizes quality management in its operations. The company is part of the Greater Artemis Life Sciences, under the Vista Group of Companies, and represents several international pharmaceutical manufacturers in Uganda, including Bliss GVS Healthcare Ltd., Fourrts Ltd., Strides Arcolab Ltd., Sance Laboratories, Universal Corporation Limited (UCL), and Xepa-Soul Pattinson (Malaysia).

The company's headquarters are located at Bombo Road, Gathani House, Kampala, Uganda. Delmaw Enterprises Ltd plays a pivotal role in Uganda's pharmaceutical distribution network, ensuring the availability of essential medicines and medical supplies across the country. By partnering with reputable international manufacturers, the company contributes significantly to the healthcare sector, addressing the diverse medical needs of the Ugandan population.

Delmaw Enterprises Ltd operates a centralized distribution model from its headquarters in Kampala. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of handling significant volumes of pharmaceutical products. The company imports a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicating a robust logistics network to manage these products efficiently. Given its strategic location in Kampala, Delmaw Enterprises Ltd is well-positioned to serve the entire Ugandan market, ensuring timely delivery of medical supplies to various regions.

In Uganda's pharmaceutical supply chain, M/s. Delmaw Enterprises Ltd functions primarily as a wholesaler and importer. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders within the healthcare sector. By representing multiple international pharmaceutical manufacturers, Delmaw Enterprises Ltd acts as a key intermediary, facilitating the availability of a wide array of medical products in Uganda. This role is crucial in ensuring that healthcare providers have access to essential medicines and medical devices necessary for patient care.

Delmaw Enterprises Ltd demonstrates a high degree of sourcing concentration, with a total import value of $600,000 USD from India across 12 shipments. The company's portfolio is entirely concentrated on two products: Cetirizine and Metformin, each accounting for $300,000 USD in imports. This indicates a strategic focus on these two therapeutic categories—Antihistamines & Allergy and Diabetes & Endocrine—suggesting that Delmaw Enterprises Ltd is capitalizing on the significant demand for these medications in the Ugandan market.

The exclusive sourcing from a single supplier, Fourrts (India) Laboratories Private Limited, which accounts for all 12 shipments, reflects a strong and stable supplier relationship. However, this single-source dependency also poses potential risks, such as supply chain disruptions or changes in supplier pricing and policies. To mitigate these risks, it would be prudent for Delmaw Enterprises Ltd to consider diversifying its supplier base and exploring alternative sources for these key products.

The resilience of Delmaw Enterprises Ltd's supply chain is closely tied to its exclusive reliance on Fourrts (India) Laboratories Private Limited for the importation of Cetirizine and Metformin. While this single-source strategy may offer benefits such as streamlined logistics and potentially favorable pricing, it also exposes the company to risks associated with supply chain disruptions, regulatory changes, or operational challenges faced by the supplier. Currently, there is no publicly available information indicating the presence of backup suppliers or alternative sourcing strategies for these critical products.

To enhance supply chain resilience, Delmaw Enterprises Ltd should consider establishing relationships with additional suppliers and diversifying its product formulations. This approach would provide greater flexibility and security, ensuring a continuous and reliable supply of essential medications to the Ugandan market.

Delmaw Enterprises Ltd's concentrated sourcing strategy positions the company as a dominant player in the Ugandan market for Cetirizine and Metformin. This focus allows the company to leverage economies of scale and establish strong relationships with its supplier, Fourrts (India) Laboratories Private Limited. However, the exclusive reliance on a single supplier and a narrow product portfolio may limit the company's ability to respond to market changes and customer demands for a broader range of pharmaceutical products.

For Indian exporters, the existing relationship between Delmaw Enterprises Ltd and Fourrts (India) Laboratories Private Limited may present challenges in entering the Ugandan market. To overcome this, Indian exporters should focus on offering differentiated products, competitive pricing, and value-added services that align with the specific needs of the Ugandan healthcare sector. Building strong relationships with local stakeholders and understanding the regulatory landscape will be crucial for establishing a foothold in this market.

The National Drug Authority (NDA) is the primary regulatory body responsible for overseeing the manufacture, importation, distribution, and licensing of pharmaceutical products in Uganda. Established in 1993, the NDA operates under the National Drug Policy and Authority Act, which provides the legal framework for drug regulation in the country.

The NDA's mandate includes ensuring the safety, efficacy, and quality of medicines available in Uganda. This involves regulating the importation and exportation of drugs, conducting inspections of manufacturing facilities, and enforcing compliance with Good Manufacturing Practices (GMP). The NDA also maintains a national list of essential drugs and formulary, which guides the importation and distribution of pharmaceutical products. (nda.or.ug)

Importers of pharmaceutical products into Uganda are required to obtain an import license from the National Drug Authority (NDA). This license is essential for ensuring that imported drugs meet the regulatory standards set by the NDA. The import license can be annual, issued to regular importers such as retail pharmacies, wholesale pharmacies, pharmaceutical manufacturers, or any organization that regularly imports drugs and related substances. Provisional import permits are issued to non-regular importers for specific consignments, typically valid for one month. (businesslicences.go.ug)

In addition to import licensing, the NDA enforces compliance with Good Manufacturing Practices (GMP) to ensure that pharmaceutical products are consistently produced and controlled according to quality standards. GMP inspections are conducted for both domestic and foreign manufacturing sites, and foreign manufacturing sites are required to pass an inspection prior to approval of the marketing authorization application. (nda.or.ug)

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy. The National Drug Authority (NDA) conducts inspections and sampling at ports of entry to ensure compliance with regulatory standards. Products are allowed entry into Uganda only through gazetted ports of entry, and importers must apply for import permits through the NDA Management Information System (NDAMIS). (nda.or.ug)

Labeling requirements for pharmaceutical products include the use of the English language and must comply with the NDA's guidelines. Specific requirements may include details such as the product name, active ingredients, dosage form, strength, batch number, manufacturing date, expiry date, storage conditions, and the name and address of the manufacturer or distributor. Serialization mandates may also apply to ensure traceability and prevent counterfeit products.

Between 2024 and 2026, the National Drug Authority (NDA) implemented several policy changes affecting pharmaceutical imports into Uganda. These changes include the introduction of electronic applications for import permits through the NDA Management Information System (NDAMIS), streamlining the importation process and enhancing efficiency. Additionally, the NDA has updated its guidelines on the verification of applications for the importation and exportation of drugs, pharmaceutical raw materials, and packaging materials, emphasizing the need for compliance with international standards. (nda.or.ug)

The NDA has also revised the National Drug Policy and Authority (Importation and Exportation of Drugs) Regulations, 2014, to align with current international best practices and address emerging challenges in the pharmaceutical sector. These regulatory changes aim to improve the quality and safety of pharmaceutical products in Uganda and ensure that imported drugs meet the required standards. (ugandatrades.go.ug)

M/s. Delmaw Enterprises Ltd's focus on importing Cetirizine and Metformin aligns with the significant demand for these medications in Uganda. Cetirizine, an antihistamine, is commonly used to treat allergy symptoms, while Metformin is a first-line medication for managing type 2 diabetes. The prevalence of allergic conditions and diabetes in Uganda underscores the importance of these drugs in the country's healthcare system.

By concentrating on these therapeutic areas, Delmaw Enterprises Ltd addresses critical health concerns and contributes to improving the quality of life